Where does Veryan Medical Limited rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Veryan Medical Limited ranks #23,634 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Veryan Medical Limited hold?

Veryan Medical Limited holds 12 US utility patents granted between 2015 and 2023, spanning 5 technology areas.

What is Veryan Medical Limited's Innovation Score?

Veryan Medical Limited has an Innovation Score of 27.2 out of 100 (23rd percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Veryan Medical Limited's patent grant rate increasing or decreasing?

Veryan Medical Limited's recent grant velocity is -50% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Veryan Medical Limited's patents?

Veryan Medical Limited's patents average 15.2 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Veryan Medical Limited patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Veryan Medical Limited

Q: What technology areas does Veryan Medical Limited focus on?

Veryan Medical Limited's top technology area is A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive DEVICES; FOMENTATION; Treatment OR Protection OF Eyes OR EARS; Bandages, Dressings OR Absorbent PADS; Firs) with 11 patents, ranking #593 of 3,082 assignees active in that subclass. Grants appear in 5 CPC subclasses total.

USPTO PatentsView assignee record - 12 granted patents across 5 technology areas, recorded in grant years 2015–2023. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Veryan ranks #23,634 of 49,997 tracked US assignees by granted-patent volume, with 12 patents across 5 technology areas.

#23,634
of 49,997 US assignees by volume: 23rd percentile
by Innovation Score (27.2/100): 15.2
avg claims per patent: -50%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R23634 · Foreign Corporation #23,634 · 12 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-DROP · BOOK-FULL

GRANTS-MICRO 12 grants
MID-PACK #23,634/49,997
PHOTO-FINISH Veeder-Root
CPC-NARROW A61F · 5 areas
INNOV-THIN 27.2/100
CLAIMS-RICH 15.2 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DROP -50% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Veeder-Root Company (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Veryan’s 27.2 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 8.9 pts (33%) Velocity 1.3 pts (5%) Breadth 7.9 pts (29%) Claim depth 9.1 pts (33%)

Qualcomm Incorporated · highest

85
Veryan Medical · this assignee

27
3D Lighting… · lowest

7

What this shows Veryan's Innovation Score is 27.2/100 (23rd percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Veryan?

Each dot is one of Veryan’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Veryan’s own 15.2 claims/patent is ABOVE the 8.1 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Veryan vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Veryan's grants concentrate

Veryan Medical Limited is a focused PatentsView assignee: 5 CPC subclasses with 91.7% of grants classified under A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device). Peak complete grant year is 2017 (2 grants) versus a trough of 1 in 2015. By volume, Veryan sits between Veeder-Root Company and Viking Access Systems, LLC.

Veryan's three-year grant acceleration

Veryan Medical Limited shows 1 grants in 2022–2024 against only 5 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Veeder-root

12
Vego Garden

12
Velossa Tech Engi…

12
Veris

12
Viamet Pharmaceut…

12
Vida Diagnostics

12
Viewsonic Interna…

12
Viking Access Sys…

12
Veryan Medical ◀

12

What this shows Veryan holds 12 patents at rank #23,634, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Veryan

By rank, the assignees closest to #23,634 in granted patent volume.

Leaders in A61F (Filters Implantable Into Blood Vessels)

Other assignees with the most granted patents in Veryan's primary technology class.

Veryan's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

27 23rd percentile higher than 23% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2023

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Veryan Medical Limited patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	1	8.3%
2016	1	8.3%
2017	2	16.7%
2018	2	16.7%
2019	2	16.7%
2020	1	8.3%
2021	2	16.7%
2023	1	8.3%

Which technologies does Veryan Medical Limited patent most?

A61F - Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive DEVICES; FOMENTATION; Treatment OR Protection OF Eyes OR EARS; Bandages, Dressings OR Absorbent PADS; Firs 11

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 2

B29C - Shaping OR Joining OF PLASTICS; Shaping OF Material IN A Plastic State, NOT Otherwise Provided FOR; After-treatment OF THE Shaped Products, e.g. Repairing 1

A61B - DIAGNOSIS; SURGERY; Identification 1

Y10S - Technical Subjects Covered BY Former Uspc Cross-reference ART Collections [XRACs] AND Digests 1

Top 5 of 5 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Veryan Medical Limited's patent record in context - here's where to go next.

Veryan Medical Limited's lead technology class is A61F (Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive Device), 91.7% of its portfolio - see every assignee active in that class. Explore A61F
Ranked #23,634 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Veryan Medical Limited against Veeder-Root Company, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 27.2/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.